|Application ||IF, ICC, E|
|Target/Specificity||Recombinant CMV-p65 protein|
|Application Note||ELISA (For coating, order Ab without BSA)|
Immunocytochemistry (Acetone or paraformaldehyde fixed) (0.5-1.0 µg/ml for 30 min)
Immunofluorescence : 0.5-1.0 µg/ml .
|Format||0.5 ml at 200ug/ml with BSA and azide|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||Cytomegalovirus p65 (CMV-p65) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop cytomegalovirus (CMV) infections. In some patients with AIDS, CMV is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of CMV disease. An indicator of active CMV infection is needed to facilitate the diagnosis of CMV disease in patients with AIDS or HIV infection. CMV p65 antigen was detected in the leukocytes of both the peripheral blood and BALF during the early phase of CMV disease.
1. Hanabusa H, Matsuda F, Tanaka Y, Uesugi T, Ota T, Sato T, Nomori H, Minematsu T, Minamishima Y, Mori R. Detection of cytomegalovirus (CMV) antigen for rapid diagnosis and monitoring of CMV diseases in AIDS. [Article in Japanese] Kansenshogaku Zasshi. 1994;68(9):1105-12.
If you have any additional inquiries please email technical services at email@example.com.